Free Trial
NASDAQ:INAB

IN8bio Q1 2026 Earnings Report

IN8bio logo
$1.45 -0.09 (-5.84%)
Closing price 04:00 PM Eastern
Extended Trading
$1.47 +0.02 (+1.38%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IN8bio EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.59
Beat/Miss
Beat by +$0.33
One Year Ago EPS
N/A

IN8bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IN8bio Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Thursday, May 7, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

IN8bio's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

IN8bio Earnings Headlines

In8bio (INAB) Stock Forecast & Price Target
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
IN8bio Unveils T-Cell Engager Data as Glioblastoma PFS Improves
See More IN8bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IN8bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IN8bio and other key companies, straight to your email.

About IN8bio

IN8bio (NASDAQ:INAB) is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

View IN8bio Profile